RMT-Epigenomex, Inc.
Reducing Time & Cost for Drug Discovery



RMT-Epigenomex, Inc. partners with biotech and pharmaceutical companies, contract research organizations and academia  to facilitate epigenetic drug discovery through significant reductions in the time and cost required to bring a new drug to market.

News and Events - October 14, 2014: RMT-Epigenomex partners with Micropharma to research protein arginine methylation in human disease related to alterations in human host microbiomes.  RMT entered into a business development agreement with Micropharma, a Canadian biotechnology company focused on human health through the microbiome.  The agreement will include exploring the status of protein arginine methylation in human disease related to alterations in human host microbiomes.

News and Events - July 15, 2014:  RMT-Epigenomex is proud to announce that it has been selected as a semifinalist in Buffalo's 43North business idea competition.  RMT was chosen from nearly 7,000 business ideas.  43North is the world's largest competition of its kind that is intended to drive new economic opportunities throughout Western New York.

Home


RMT-Epigenomex, Inc. (RMT) partners with biotech, pharmaceutical companies, contract research organizations and academia  to facilitate epigenetic drug discovery through significant reductions in the time and cost required to bring a new drug to market.  RMT continues to build a patent portfolio that exploits a unique protein structural signature to innovate a series of detection assays, reagents and drug screening/diagnostic procedures that will facilitate drug discovery and significantly shorten the timeline of the development pipeline.  Although the direct applicability of RMT-Epigenomex technology is currently most relevant to the exciting field of epigenetics, the basic biology that has been revealed as a result of RMT’s technology is also likely to be useful, even disruptive, for traditional drug development.